APA (7th ed.) Citation

W, L., G, H., & P, C. (2024). Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer. Frontiers in public health, 12, 1213318. https://doi.org/10.3389/fpubh.2024.1213318

Chicago Style (17th ed.) Citation

W, Liu, Huo G, and Chen P. "Cost-effectiveness of First-line Versus Second-line Use of Brigatinib Followed by Lorlatinib in Patients with ALK-positive Non-small Cell Lung Cancer." Frontiers in Public Health 12 (2024): 1213318. https://doi.org/10.3389/fpubh.2024.1213318.

MLA (9th ed.) Citation

W, Liu, et al. "Cost-effectiveness of First-line Versus Second-line Use of Brigatinib Followed by Lorlatinib in Patients with ALK-positive Non-small Cell Lung Cancer." Frontiers in Public Health, vol. 12, 2024, p. 1213318, https://doi.org/10.3389/fpubh.2024.1213318.